Meanwhile, the combination of the nanomedicine and anti‐PD‐L1 antibody hindered the growth of tumors and increased the level of CD8+ T cells and ratio of CD8+ T cells/T lymphocytes in the tumor, leading to an immune memory effect on inhibiting tumor metastasis (Figure 10b–e).[87] In addition, Li and co‐workers developed a GSH and ROS dual‐responsive nanomedicine to achieve the on‐demand delivery and release of the ICD inducer and immune modulators IDOi. Here, CD8A is linked to neoplasm.